PPARG and chronic myelogenous leukemia, BCR-ABL1 positive: These data should be considered with caution though, as another recent study showed that PPARγ agonist pioglitazone in combination with imatinib is efficient in making LSC exit quiescence to enter apoptosis in human BCR-ABL+ CML [142].